[Electroclinical evaluation of the effectiveness of a new benzodiazepine, Ro 5-4023].
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D001247:Asthenia / Q000139:chemically induced; D001552:Benzazepines / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004569:Electroencephalography; D004827:Epilepsy / Q000188:drug therapy*; D004830:Epilepsy, Tonic-Clonic / Q000188:drug therapy; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D007659:Ketones / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009574:Nitro Compounds / Q000009:adverse effects / Q000627:therapeutic use; D012893:Sleep Wake Disorders / Q000139:chemically induced
D000927:Anticonvulsants; D001552:Benzazepines; D007659:Ketones; D009574:Nitro Compounds
Valutazione elettro-clinica dell'efficacia della nuova benzodiazepina Ro 5-4023.